title: Varicella zoster virus disease after pediatric living donor liver transplantation: is it serious?
abstract: OBJECTIVE
  The aim of this study was to evaluate patients who developed varicella zoster virus (VZV) disease after pediatric living donor liver transplantation (PLDLT).
  
  
  METHODS
  Two hundred fifty-five patients who underwent PLDLT between 1995 and 2010 were included in this study. Pretransplantation vaccination of VZV was performed for all recipients except emergency PLDLTs. Posttransplantation VZV vaccination was administered to the patients with a low VZV antibody titer 2 years or more after transplantation. The clinical course and outcomes of VZV disease in cases were reviewed with the transplant database and hospital medical records.
  
  
  RESULTS
  Sixty-three patients developed VZV disease (chicken pox in 61, herpes zoster in 2) at a median onset of 36 months after PLDLT and at a median age of 4 years old, with a cumulative incidence of 25%. All chicken pox occurred in VZV antibody-negative patients. The onset of herpes zoster in the two patients occurred within 3 months after PLDLT; in addition, these patients were VZV antibody-positive patients. The clinical presentations of most patients were not serious and there were no disseminated infections. Although only 3 patients (5%) were hospitalized, the other 60 patients (95%) all showed a good response to oral antiviral therapy.
  
  
  CONCLUSIONS
  Although VZV disease is an infectious disease with a high morbidity rate after PLDLT, it can normally be successfully managed on an outpatient basis at home. Pre- and posttransplantation vaccinations are effective for delaying the onset of chicken pox after PLDLT and to prevent it from developing into a serious illness.
authors.affiliation: Department of Transplant Surgery, Jichi Medical University, Shimotsuke-shi, Tochigi, Japan. koimizu@jichi.ac.jp
authors.forename: K
authors.initials: K
authors.lastname: Mizuta
authors.forename: T
authors.initials: T
authors.lastname: Urahashi
authors.forename: Y
authors.initials: Y
authors.lastname: Ihara
authors.forename: Y
authors.initials: Y
authors.lastname: Sanada
authors.forename: T
authors.initials: T
authors.lastname: Wakiya
authors.forename: N
authors.initials: N
authors.lastname: Yamada
authors.forename: N
authors.initials: N
authors.lastname: Okada
authors.forename: S
authors.initials: S
authors.lastname: Egami
authors.forename: H
authors.initials: H
authors.lastname: Kawarasaki
mesh_terms: D000212:Acyclovir / Q000008:administration & dosage; D000914:Antibodies, Viral / Q000097:blood; D000998:Antiviral Agents / Q000008:administration & dosage; D002644:Chickenpox / Q000209:etiology* / Q000517:prevention & control; D002648:Child; D014645:Herpesvirus 3, Human / Q000276:immunology; D006801:Humans; D007124:Immunoenzyme Techniques; D016031:Liver Transplantation; D019520:Living Donors
chemical_list: D000914:Antibodies, Viral; D000998:Antiviral Agents; D000212:Acyclovir